CA2960101C - Substituted carboline derivative and compositions thereof useful as camkii inhibitors - Google Patents

Substituted carboline derivative and compositions thereof useful as camkii inhibitors Download PDF

Info

Publication number
CA2960101C
CA2960101C CA2960101A CA2960101A CA2960101C CA 2960101 C CA2960101 C CA 2960101C CA 2960101 A CA2960101 A CA 2960101A CA 2960101 A CA2960101 A CA 2960101A CA 2960101 C CA2960101 C CA 2960101C
Authority
CA
Canada
Prior art keywords
compound
disorder
condition
disease
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2960101A
Other languages
English (en)
French (fr)
Other versions
CA2960101A1 (en
Inventor
Daniel E. Levy
Howard Schulman
Bheema Rao Paraselli
Nangunoori Sampath KUMAR
Brahmaiah DABBUGODDU
Chundru BALASUBRAMANYAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA2960101A1 publication Critical patent/CA2960101A1/en
Application granted granted Critical
Publication of CA2960101C publication Critical patent/CA2960101C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2960101A 2014-09-05 2015-09-04 Substituted carboline derivative and compositions thereof useful as camkii inhibitors Active CA2960101C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046450P 2014-09-05 2014-09-05
US62/046,450 2014-09-05
PCT/US2015/048640 WO2016037106A1 (en) 2014-09-05 2015-09-04 CaMKII INHIBITORS AND USES THEREOF

Publications (2)

Publication Number Publication Date
CA2960101A1 CA2960101A1 (en) 2016-03-10
CA2960101C true CA2960101C (en) 2024-05-21

Family

ID=54150675

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2960101A Active CA2960101C (en) 2014-09-05 2015-09-04 Substituted carboline derivative and compositions thereof useful as camkii inhibitors

Country Status (7)

Country Link
US (2) US10759792B2 (enExample)
EP (1) EP3189052B1 (enExample)
JP (2) JP6782227B2 (enExample)
CN (1) CN107074856A (enExample)
AU (2) AU2015311730A1 (enExample)
CA (1) CA2960101C (enExample)
WO (1) WO2016037106A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US11376302B2 (en) 2017-09-10 2022-07-05 Carmel Haifa University Economic Corporation Ltd. Methods for treating depression and major depressive disorder
CN108218862B (zh) * 2018-02-07 2020-06-23 贵州医科大学 α-卡波林类衍生物在制备抗心肌缺氧复氧损伤药物中的应用
MX2020008581A (es) 2018-02-21 2020-09-21 Bristol Myers Squibb Co Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos.
CN108904532B (zh) * 2018-08-20 2021-07-27 上海市第一人民医院 一种富勒烯C60纳米晶体联合CaMKII抑制剂的组合物的应用
WO2020109191A1 (en) * 2018-11-27 2020-06-04 F. Hoffmann-La Roche Ag Aryl compounds for the treatment and prophylaxis of bacterial infection
JP7824282B2 (ja) * 2020-09-28 2026-03-04 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1913124A (en) * 1932-01-02 1933-06-06 American Sundries Co Inc Vaporizer
US2690441A (en) * 1953-06-11 1954-09-28 Searle & Co 3-carboline derivatives
GB1268773A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
BE758991A (fr) * 1969-11-18 1971-05-17 Reeves Bros Inc Procede de reticulation hydrodynamique d'une mousse de polyurethanne
PL80610B1 (enExample) * 1970-03-12 1975-08-30
GB8600651D0 (en) * 1986-01-11 1986-02-19 Beecham Group Plc Compounds
DE4435477A1 (de) 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
JP2001509808A (ja) 1997-01-31 2001-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 多機能性カルシウム／カルモジュリン−依存性プロテインキナーゼの阻害による不整脈の処置
NZ532327A (en) 2001-10-01 2005-10-28 Univ Vanderbilt Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
WO2004058764A1 (en) 2002-12-27 2004-07-15 Bayer Healthcare Ag 4-phenyl-pyrimido [4,5-b] indole derivatives
US20060057639A1 (en) 2004-06-16 2006-03-16 Pitt Geoffrey S CaMKII/calcium channel phosphorylation-related compositions and methods
FR2876377B1 (fr) * 2004-10-11 2007-03-16 Univ Claude Bernard Lyon Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
CA2589808A1 (en) 2004-11-02 2006-05-11 Dainippon Sumitomo Pharma Co., Ltd. Combination drug for treating autoimmune disease
RU2387653C2 (ru) * 2005-05-16 2010-04-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназ
EP2354140A1 (en) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
EP1896472A1 (de) * 2005-06-09 2008-03-12 Boehringer Ingelheim International GmbH Alpha-carboline als cdk-1 inhibitoren
JP2009500475A (ja) 2005-07-01 2009-01-08 ザ テキサス エイ アンド エム ユニヴァーシティ システム 酸化亜鉛ポリマーナノ複合材料及び酸化亜鉛ポリマーナノ複合材料の製造方法
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
CL2008001540A1 (es) 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
EP2247558B2 (en) * 2008-02-14 2024-07-03 Eli Lilly and Company Novel imaging agents for detecting neurological dysfunction
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
JP2011530512A (ja) 2008-08-06 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション カルシウムチャネル遮断薬としての置換ジヒドロイソキノリノン及びイソキノリンジオン誘導体
EP2161271A1 (en) * 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
TWI477503B (zh) 2008-10-31 2015-03-21 Medivation Technologies Inc 含有剛性部分之吡啶并〔４，３－ｂ〕吲哚
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤
US8440656B2 (en) 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
WO2011159857A1 (en) 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
CA2849057C (en) * 2011-09-19 2021-05-11 Vitas Pharma Research Pvt Ltd Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections
KR102215272B1 (ko) * 2012-09-28 2021-02-15 이그니타, 인코포레이티드 비정형 단백질 키나제 c의 아자퀴나졸린 억제제
US9951061B2 (en) 2013-03-06 2018-04-24 Allosteros Therapeutics, Inc. CaMKII inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2020203927B9 (en) 2021-07-08
AU2020203927B2 (en) 2021-06-24
US10759792B2 (en) 2020-09-01
JP2017534572A (ja) 2017-11-24
US20200385383A1 (en) 2020-12-10
JP2020143161A (ja) 2020-09-10
US11325908B2 (en) 2022-05-10
AU2015311730A8 (en) 2017-05-11
AU2020203927A1 (en) 2020-07-02
AU2015311730A1 (en) 2017-04-20
CN107074856A (zh) 2017-08-18
WO2016037106A1 (en) 2016-03-10
JP6782227B2 (ja) 2020-11-11
EP3189052B1 (en) 2021-11-03
JP6918378B2 (ja) 2021-08-11
CA2960101A1 (en) 2016-03-10
US20170247374A1 (en) 2017-08-31
EP3189052A1 (en) 2017-07-12

Similar Documents

Publication Publication Date Title
AU2020203927B9 (en) CaMKII inhibitors and uses thereof
US11555026B2 (en) AHR inhibitors and uses thereof
EP2964225B1 (en) CaMKII INHIBITORS AND USES THEREOF
EP2903613B1 (en) Pyrazole derivatives useful as inhibitors of irak4 activity
CA3088927A1 (en) Biaryl derivative, preparation method therefor and pharmaceutical use thereof
CA3150701A1 (en) Alkynyl quinazoline compounds
US20250051367A1 (en) Heterocycle-containing lonp1 inhibitor compounds, uses and methods
EA042939B1 (ru) Ингибиторы арил-гидрокарбонового рецептора (ahr) и их применение

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200806

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251211

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260325

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260415